Adela Mattiazzi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4018166/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Graft Failure Due to Nonadherence among 150 Prospectively-Followed Kidney Transplant Recipients at 18 Years Post-transplant: Our Results and Review of the Literature. Journal of Clinical Medicine, 2022, 11, 1334.	2.4	3
2	Antimicrobial resistance and recurrent bacterial urinary tract infections in hospitalized patients following kidney transplantation: A single enter experience. Transplant Infectious Disease, 2020, 22, e13337.	1.7	5
3	Assessing the link between modified †Teach Back' method and improvement in knowledge of the medical regimen among youth with kidney transplants: The application of digital media. Patient Education and Counseling, 2019, 102, 1035-1039.	2.2	13
4	A cluster of donorâ€derived <i><scp>C</scp>ryptococcus neoformans</i> infection affecting lung, liver, and kidney transplant recipients: Case report and review of literature. Transplant Infectious Disease, 2018, 20, e12836.	1.7	22
5	Antibodyâ€mediated rejection implies a poor prognosis in kidney transplantation: Results from a single center. Clinical Transplantation, 2018, 32, e13392.	1.6	4
6	Phaeohyphomycosis due to <i>Exophiala</i> infections in solid organ transplant recipients: Case report and literature review. Transplant Infectious Disease, 2017, 19, e12723.	1.7	17
7	Randomized trial of rATg/Daclizumab vs. rATg/Alemtuzumab as dual induction therapy in renal transplantation: Results at 8years of follow-up. Transplant Immunology, 2017, 40, 42-50.	1.2	13
8	Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation. Transplant International, 2016, 29, 216-226.	1.6	48
9	Impact of antiretroviral therapy on clinical outcomes in HIV+ kidney transplant recipients: Review of 58 cases. F1000Research, 2016, 5, 2893.	1.6	24
10	Predictors of reduced tacrolimus dose and trough level through 36 months postâ€ŧransplant among 578 adult primary kidney transplant recipients. Clinical Transplantation, 2014, 28, 470-478.	1.6	2
11	Randomized Trial of Three Induction Antibodies in Kidney Transplantation. Transplantation, 2014, 97, 1128-1138.	1.0	33
12	Lack of clinical association and effect of peripheral WBC counts on immune cell function test in kidney transplant recipients with T-cell depleting induction and steroid-sparing maintenance therapy. Transplant Immunology, 2014, 30, 88-92.	1.2	10
13	Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation. Transplant Immunology, 2011, 25, 104-111.	1.2	26
14	A Randomized Trial of Three Renal Transplant Induction Antibodies: Early Comparison of Tacrolimus, Mycophenolate Mofetil, and Steroid Dosing, and Newer Immune-Monitoring1. Transplantation, 2005, 80, 457-465.	1.0	204
15	A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. Ii. Survival, function, and protocol compliance at 1 year. Transplantation, 2004, 77, 252-258.	1.0	140
16	A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation, 2004, 77, 244-251.	1.0	115
17	The Use of Campath-1H as Induction Therapy in Renal Transplantation: Preliminary Results. Transplantation, 2004, 78, 426-433.	1.0	113